"And since no such study was ever done," she told the jury, "you would not expect to find any specific study that would have been able to analyze interrupted aortic arch Type A as a specific subgroup."
Most of the studies, she said, "just reported on all cardiac malformations as a group and even those that ... did any kind of subgroup analysis restricted them to the most common subgroups."
There were several studies where they restricted any analysis to subgroups where they had at least 200 women whose child suffered a specific birth defect, "which would automatically exclude IAA Type A," she explained.
The Louik paper restricted the analysis to subgroups of 100, she said. But the "Louik study itself very clearly lists IAA as a specific cardiac malformation under conotruncal defects in their appendix where they list specific subgroups that they looked at and considered," Kramer told the jury.
Louik Study
The Louik study was funded by Glaxo and conducted out of the Slone Epidemiology Center For Birth Defects. While Kramer was testifying earlier, Tracey put up a slide entitled, "Louik, et al - GSK involvement," and told her to tell "the jury what GSK's involvement in this study was both publicly and then privately."
Davis objected to this testimony. "There is nothing in Doctor Kramer's expert report that discusses anything about communications with GSK that somehow impacted the Louik study, so there has been no notice to GSK that she would be offering those opinions today," he argued to the judge, while the jury was out of the courtroom.
"Your Honor," Tracey told the judge, "this issue is something that has been percolating for a number of years."
Next Page 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).